NCT04893486 2024-08-29
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
Palvella Therapeutics, Inc.
Phase 2 Completed
Palvella Therapeutics, Inc.
Sol-Gel Technologies, Ltd.
PellePharm, Inc.
PellePharm, Inc.
Novartis
Novartis
Novartis